Showing items 1051-1075 of 1137 (46 Page(s) Totally)
<< < 37 38 39 40 41 42 43 44 45 46 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2018 |
Response to Stephane Renaud et al.
|
Hsu F.-M.; CHAO-CHI HO; Yang W.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2018 |
Response to Stephane Renaud et al.
|
Yang W.-C.;Shih J.-Y.;Chao-Chi Ho;Hsu F.-M.; Yang W.-C.; Shih J.-Y.; CHAO-CHI HO; Hsu F.-M. |
| 臺大學術典藏 |
2018 |
Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion
|
Shih J.-Y.; Yang J.C.-H.; Yu C.-J.; Liu Y.-N.; SHANG-GIN WU; Shang-Gin Wu;Liu Y.-N.;Yu C.-J.;Yang J.C.-H.;Shih J.-Y. |
| 臺大學術典藏 |
2018 |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Chia-Lin Hsu;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; CHIA-LIN HSU; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2018 |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liao W.-Y.; MENG-RUI LEE; Liang S.-K.; Ho C.-C.; Ko J.-C.; Shih J.-Y. |
| 國立成功大學 |
2018 |
In-hospital implementation of evidence-based, medications is associated with improved survival, in diabetic patients with acute coronary, syndrome - Data from TSOC ACS-DM registry
|
Chen, K.-C.;Yin, W.-H.;Wu, C.-C.;Chan, S.-H.;Wu, Y.-W.;Wang, K.Y.;Chang, K.-C.;Hwang, J.-J.;Voon, W.-C.;Hsieh, I.-C.;Chong, J.-T.;Lin, W.-S.;Hsu, C.-N.;Ueng, K.-C.;Hsia, C.-P.;Liu, J.-C.;Yeh, J.-S.;Mar, G.-Y.;Shih, J.-Y.;Kuo, J.-Y.;Tsao, H.-M.;Tseng, W.-K.;Yang, C.-H.;Chang, Chang C.-C.;Chiang, Chiang C.-E.;Lei, M.-H.;Lin, J.-F.;Shyu, K.-G. |
| 國立成功大學 |
2018 |
Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials
|
Yen, C.-J.;Muro, K.;Kim, T.-W.;Kudo, M.;Shih, J.-Y.;Lee, K.-W.;Chao, Y.;Kim, S.-W.;Yamazaki, K.;Sohn, J.;Cheng, R.;Zhang, Y.;Binder, P.;Mi, G.;Orlando, M.;Chung, H.C. |
| 國立臺灣科技大學 |
2017 |
Mechanical properties and microstructural analysis of slag based cementitious binder with calcined dolomite as an activator
|
Djayaprabha, H.S;Chang, T.-P;Shih, J.-Y;Chen, Chen C.-T. |
| 國立臺灣科技大學 |
2017 |
Life cycle guideline of petrochemical plant underground piping system
|
Shih, J.-Y.;Hsiao, S.-Y.;Chang, T.-P. |
| 臺大學術典藏 |
2017 |
Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
|
Wu S.-G.;Yih-Leong Chang;Yu C.-J.;Yang P.-C.;Shih J.-Y.; Wu S.-G.; YIH-LEONG CHANG; Yu C.-J.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2017 |
Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain?after Sequential Use of ALK Inhibitors
|
Wang H.-Y.; CHAO-CHI HO; Shih J.-Y.; CHAO-CHI HO |
| 臺大學術典藏 |
2017 |
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
|
Liao W.-Y.; Lin C.-A.; Shih J.-Y.; CHONG-JEN YU; Chih-Hsin Yang J.; Ho C.-C.; Ho C.-C.;Liao W.-Y.;Lin C.-A.;Shih J.-Y.;Chong-Jen Yu;Chih-Hsin Yang J. |
| 臺大學術典藏 |
2017 |
Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression
|
Chen C.-Y.;Chen Y.-Y.;Chen J.J.W.;Chen K.-Y.;Ho C.-C.;Shih J.-Y.;Chang Y.-L.;Yu C.-J.;Pan-Chyr Yang; Chen C.-Y.; Chen Y.-Y.; Chen J.J.W.; Chen K.-Y.; Ho C.-C.; Shih J.-Y.; Chang Y.-L.; Yu C.-J.; PAN-CHYR YANG |
| 臺大學術典藏 |
2017 |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; MENG-RUI LEE; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 國立臺灣科技大學 |
2016 |
Engineering properties and durability of high-strength self-compacting concrete with no-cement SFC binder
|
Nguyen, H.-A;Chang, T.-P;Shih, J.-Y;Chen, Chen C.-T;Nguyen, T.-D. |
| 國立臺灣科技大學 |
2016 |
Sulfate resistance of low energy SFC no-cement mortar
|
Nguyen, H.-A;Chang, T.-P;Shih, J.-Y;Chen, Chen C.-T;Nguyen, T.-D. |
| 臺大學術典藏 |
2016 |
Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations
|
Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; YIH-LEONG CHANG; Yu C.-J.; Yang J.C.-H.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2016 |
151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs
|
Liao B.-C.;Bai Y.-Y.;Lin C.-C.;Lin S.-Y.;Lee Y.-F.;Chao-Chi Ho;Shih J.-Y.;Chang Y.-C.;Yu C.-J.;Yang J.; Liao B.-C.; Bai Y.-Y.; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; CHAO-CHI HO; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Yang J. |
| 臺大學術典藏 |
2016 |
151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs
|
Liao B.-C.; Bai Y.-Y.; Lin C.-C.; Lin S.-Y.; YEE-FAN LEE; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Yang J. |
| 臺大學術典藏 |
2016 |
Association of BIM deletion polymorphism with intrinsic resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
|
SHANG-GIN WU; Liu Y.-N.; Yu C.-J.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2016 |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Chen L.-Y.; Molina-Vila M.A.; Ruan S.-Y.; Su K.-Y.; Liao W.-Y.; KAI-LUN YU; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.H.; Rosell R.; Yang P.-C. |
| 國立臺灣科技大學 |
2015 |
Influence of circulating fluidized bed combustion (CFBC) fly ash on properties of modified high volume low calcium fly ash (HVFA) cement paste
|
Nguyen, H.-A.;Chang, T.-P.;Shih, J.-Y.;Chen, C.-T.;Nguyen, T.-D. |
| 國立臺灣大學 |
2015 |
EGFR Mutation Status Is Associated With Better Radiographic Response and Predicts Favorable Outcomes in Non-Small Cell Lung Cancer Patients With Brain Metastases Treated by Stereotactic Radiosurgery
|
Yang, W. C.; Xiao, F. R.; Shih, J. Y.; Ho, C. C.; Chen, Y. F.; Tseng, H. M.; Chen, K. Y.; Liao, W. Y.; Yu, C. J.; Yang, J. C. H.; Kuo, S. H.; Cheng, J. C. H.; Yang, P. C.; Hsu, F. M.; 曾漢民; 陳雅芳; 楊泮池; 廖唯昱; 郭頌鑫; 陳冠宇; 余忠仁; 成佳憲; 何肇基; 蕭輔仁; 施金元; 許?銘 |
| 臺大學術典藏 |
2015 |
Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy
|
Yang J.C.H.; Shih J.Y; Chia-Chi Lin; Liao B.C |
| 臺大學術典藏 |
2015 |
Epidermal growth factor receptor tyrosine Kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations
|
Chih-Hsin Yang;Perng R.-P;Tsai C.-M;Chang F.-K;Chuang C.-Y;Yu-Wung Yeh D;Lin C.-B;Lee K.-Y;Lai C.-L;Wu M.-F;Hsia T.-C;Ho C.-L;Lin Y.-C;Hsiao S.-H;Wang C.-C;Lai R.-S;Su W.-C;Huang M.-S;Shih J.-Y;Yang C.-T;Chiu C.-H; Chiu C.-H; Yang C.-T; Shih J.-Y; Huang M.-S; Su W.-C; Lai R.-S; Wang C.-C; Hsiao S.-H; Lin Y.-C; Ho C.-L; Hsia T.-C; Wu M.-F; Lai C.-L; Lee K.-Y; Lin C.-B; Yu-Wung Yeh D; Chuang C.-Y; Chang F.-K; Tsai C.-M; Perng R.-P; Chih-Hsin CHIH-HSIN YANG |
Showing items 1051-1075 of 1137 (46 Page(s) Totally)
<< < 37 38 39 40 41 42 43 44 45 46 > >>
View [10|25|50] records per page
